Brainstorm Cell Therapeutics Inc. has announced that the United States District Court for the Southern District of New York has granted preliminary approval for a proposed settlement concerning a stockholder derivative action. This development is crucial for the company as it seeks to resolve ongoing litigation and improve its corporate governance practices.

The preliminary approval order, issued on November 10, 2026, pertains to the case titled In re Brainstorm Cell Therapeutics, Inc. Derivative Litigation, No. 1:24-cv-01095-DEH. The company is now required to disclose the details of the settlement to its stockholders through a Notice of Pendency and Proposed Settlement of Stockholder Derivative Matters, along with a Stipulation and Agreement of Settlement.

Background

Brainstorm Cell Therapeutics Inc. operates in the biological products sector, specifically focusing on products that do not include diagnostic substances (SIC 2836). The company trades under the ticker symbol BCLI on the OTC exchange. Recent filings include a 10-Q on November 16, 2026, and another 8-K on the same date, indicating ongoing financial activities and disclosures.

What the Filing Says

The recent SEC filing states, "On November 10, 2026, the United States District Court for the Southern District of New York... entered an order... preliminarily approving the proposed settlement of the putative stockholder derivative action." The filing also notes that the company is making disclosures to its stockholders in accordance with the Court’s order.

Impact

This settlement could significantly affect Brainstorm's stockholders, as it aims to resolve claims against certain current and former directors and officers of the company. By settling these derivative matters, Brainstorm may enhance its corporate governance and potentially restore investor confidence, which is crucial in the competitive biological products industry.

What's Next

The filing does not specify the next steps following the preliminary approval of the settlement. However, the company will likely continue to communicate with its stockholders regarding the final approval process and any subsequent governance reforms that may arise from the settlement.